Posted by Michael Wonder on 05 Aug 2020
MYR Pharmaceuticals receives conditional marketing authorisation by the European Commission for Hepcludex
4 August 2020 - MYR Pharmaceuticals is pleased to announce that the European Commission has granted the Conditional marketing authorisation for their lead compound Hepcludex.
Hepcludex has been approved as the first treatment option for adult patients with chronic hepatitis delta virus infection and compensated liver disease in Europe.
